Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Sutro Biopharma, Inc. (STRO) had Receiveable Turnover of 7.20 for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$62.04M |
|
$-227.46M |
|
-- |
|
$62.04M |
|
$300.50M |
|
$-238.45M |
|
$13.36M |
|
$-225.10M |
|
$-225.10M |
|
$-227.46M |
|
$-227.46M |
|
$-227.46M |
|
$-227.46M |
|
$-238.45M |
|
$-240.95M |
|
76.83M |
|
76.83M |
|
$-2.96 |
|
$-2.96 |
|
| Balance Sheet Financials | |
$343.31M |
|
$18.19M |
|
$43.90M |
|
$387.21M |
|
$131.89M |
|
-- |
|
$210.71M |
|
$342.61M |
|
$44.60M |
|
$44.60M |
|
$44.60M |
|
82.53M |
|
| Cash Flow Statement Financials | |
$-191.54M |
|
$218.51M |
|
$94.05M |
|
$70.14M |
|
$191.16M |
|
$121.02M |
|
$24.69M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.60 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-384.34% |
|
-384.34% |
|
-388.37% |
|
-362.81% |
|
-366.62% |
|
$-194.64M |
|
-- |
|
-- |
|
-- |
|
0.16 |
|
-- |
|
|
Receiveable Turnover |
7.20 |
50.69 |
|
-509.99% |
|
-509.99% |
|
-58.74% |
|
-509.99% |
|
$0.54 |
|
$-2.53 |
|
$-2.49 |
|